Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936676 · ClinicalTrials.gov registry record
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
A clinical trial of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- 684
- Enrollment target
- 20
- Study locations
NCT00936676: Completed study of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT00936676 is a study of Parkinson's Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 684 participants, roughly in line with the 631-participant average among 158 other Parkinson's Disease trials with a reported enrollment target. The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00936676, a study of Parkinson's Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- 684 participants
- Enrollment target
- 20
- Study locations
Study Summary
Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical benefit from restarting treatment can also be considered for enrollment in the Core follow-up study period. Use of any other anti-PD treatment is permitted as deemed necessary by the treating physician (according to the participants clinical status).
Primary Outcome
Assess Benefits of rasagiline treatment using yes/no questions; Milestones of time to treatment-Dopaminergic treatment, levodopa, surgery for PD, time to -dyskinesia, hallucinations, functional decline using an aggregate of the responses to PD Functional Status Questionnaire
Conditions Studied
Interventions
- DRUG rasagiline mesylate
Study Locations (20)
California
- Teva Investigational Site 7018 - Irvine
- Teva Investigational Site 7019 - La Jolla
- Teva Investigational Site 7039 - Loma Linda
- Teva Investigational Site 7023 - Los Angeles
- Teva Investigational Site 7022 - Sunnyvale
Florida
- Teva Investigational Site 7020 - Boca Raton
- Teva Investigational Site 7011 - Gainesville
- Teva Investigational Site 7045 - Miami
- Teva Investigational Site 7017 - Tampa
Illinois
- Teva Investigational Site 7013 - Chicago
- Teva Investigational Site 7052 - Chicago
- Teva Investigational Site 7001 - Northbrook
- Teva Investigational Site 7008 - Springfield
Connecticut
- Teva Investigational Site 7024 - Danbury
- Teva Investigational Site 7016 - Farmington
Georgia
- Teva Investigational Site 7055 - Atlanta
- Teva Investigational Site 7043 - Augusta
Alabama
- Teva Investigational Site 7054 - Birmingham
Arizona
- Teva Investigational Site 7006 - Tucson
Iowa
- Teva Investigational Site 7037 - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-03 |
What the finished NCT00936676 record still lists
NCT00936676 is an observational study that tracks outcomes without assigning an intervention. The registered 684 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 631-participant average among 158 other Parkinson's Disease trials with a reported enrollment target.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which rasagiline mesylate is the first listed.
NCT00936676 names 20 study sites across 8 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00936676 about?
NCT00936676 is a clinical study titled "ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects". Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical benefit from resta...
What is the current status of trial NCT00936676?
This trial is currently completed. The enrollment target is 684 participants. The study started on 2009-07. Estimated completion is 2013-03.
What conditions does trial NCT00936676 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00936676?
The interventions under investigation include: rasagiline mesylate (DRUG).
Who is sponsoring clinical trial NCT00936676?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00936676 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00936676's enrollment target sits among peer trials
684 12th of 158 higher than 147 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
RECRUITING
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06795087 · 684 participants
Discharge Medication Use Post-Operatively in GU Cancer Patients
- NCT05099770 · 685 participants · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- NCT05880199 · 685 participants
BSGM to Evaluate Patients With GI Symptoms
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia